All In Biotech

Drug Trial Radar · NCT05507203

ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 639 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

639

Actual

Start

Nov 16, 2022

Primary completion

Jun 24, 2025

Study completion Jun 25, 2025

Sponsor

Lead sponsor
Abivax S.A.Industry
Sponsor type
Industry
First posted
Aug 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors\].

Conditions

  • Ulcerative Colitis

Interventions

  • ABX464Drug

    Administered once daily in the morning with food

  • PlaceboDrug

    Administered once daily in the morning with food

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects Who Achieve Clinical Remission Per Modified Mayo Score at Week 8Time frame: 8 weeks

Locations

264 sites in 24 countries. Site status is shown where the registry gives one.

  • Digestive Health Specialists of the Southeast

    Dothan, Alabama

  • Lakeview Clinical Research

    Guntersville, Alabama

  • Birmingham Digestive Health Research

    Homewood, Alabama

  • GI Alliance

    Sun City, Arizona

  • Del Sol Research Management, LLC

    Tucson, Arizona

  • Gastro Care Institute

    Lancaster, California

  • California Medical Research Associates Inc.

    Northridge, California

  • Clinnova Research Solutions

    Orange, California

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado

  • Clinical Research Of Brandon, LLC

    Brandon, Florida

  • Access Research Institute

    Brooksville, Florida

  • Nature Coast Clinical Research - Inverness

    Inverness, Florida

  • Auzmer Research

    Lakeland, Florida

  • Medical Professional Clinical Research Center

    Miami, Florida

  • Advanced Research Institute, Inc.

    New Port Richey, Florida

  • Endoscopic Research, Inc.

    Orlando, Florida

  • Orlando Health-Orlando Regional Medical Center

    Orlando, Florida

  • Advanced Research Institute, Inc.

    Orlando, Florida

  • Gastroenterology Associates of Pensacola, PA

    Pensacola, Florida

  • Theia Clinical Research Centers, LLC

    Temple Terrace, Florida

  • One Health Research Clinic Atlanta, LLC

    Norcross, Georgia

  • Eagle Clinical Research

    Chicago, Illinois

  • GI Alliance

    Glenview, Illinois

  • GI Alliance

    Gurnee, Illinois

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • University of Kansas Medical Center Research Institute, Inc.

    Kansas City, Kansas

  • Lucida Clinical Trials LLC

    New Bedford, Massachusetts

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

  • Rochester Clinical Research

    Rochester, New York

  • Charlotte Gastroenterology and Hepatology, P.L.L.C

    Charlotte, North Carolina

  • Care Access Research Lumberton

    Lumberton, North Carolina

  • Wexner Medical Center

    Columbus, Ohio

  • DSI Research LLC

    Springboro, Ohio

  • Gastroenterology Center of the MidSouth PC

    Germantown, Tennessee

  • GI Alliance - Southlake

    Austin, Texas

  • Central Texas Clinical Research, LLC

    Austin, Texas

  • Novel Research LLC

    Bellaire, Texas

  • Texas Digestive Disease Consultants

    Cedar Park, Texas

  • Baylor Scott and White

    Dallas, Texas

  • Cook Children's Medical Center

    Fort Worth, Texas

Showing 40 of 264 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.